中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 5
May  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(5): 1191-1196

Current research status of prognostic models for transjugular intrahepatic portosystemic shunt

DOI: 10.3969/j.issn.1001-5256.2023.05.030

  • Department of Gastroenterology, Air Force Medical Center, Beijing 100142, China

Research funding:

National Natural Science Foundation of China (81873562)

More Information
  • Corresponding author: HAN Zheyi, zheyihan_fmmu@163.com (ORCID: 0000-0002-0651-9810)
  • Received Date: 2022-09-18
  • Accepted Date: 2022-11-21
  • Published Date: 2023-05-20
    Abstract
  • Transjugular intrahepatic portosystemic shunt (TIPS) is a safe and effective method for the treatment of portal hypertension complications in patients with decompensated liver cirrhosis. At present, there are many prognostic scoring tools for risk stratification of poor prognosis after TIPS. This article briefly introduces seven prognostic scoring tools commonly used for TIPS and summarizes the clinical research evidence of each scoring tool. The literature review shows that there is currently no sufficient research evidence to determine the optimal prognostic scoring tool after TIPS. Future clinical studies should comprehensively explore the advantages and disadvantages of different scoring tools in predicting short- and long-term adverse prognostic events after TIPS and develop new prognostic scoring tools in combination with new prognostic markers.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    ROSSLE M. TIPS: 25 years later[J]. J Hepatol, 2013, 59(5): 1081-1093. DOI: 10.1016/j.jhep.2013.06.014.
    [2]
    BETTINGER D, SCHULTHEISS M, BOETTLER T, et al. Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS)[J]. Aliment Pharmacol Ther, 2016, 44(10): 1051-1061. DOI: 10.1111/apt.13809.
    [3]
    LEE EW, KUEI A, SAAB S, et al. Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt[J]. World J Gastroenterol, 2016, 22(25): 5780-5789. DOI: 10.3748/wjg.v22.i25.5780.
    [4]
    SALERNO F, MERLI M, CAZZANIGA M, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt[J]. J Hepatol, 2002, 36(4): 494-500. DOI: 10.1016/s0168-8278(01)00309-9.
    [5]
    ALLEGRETTI AS, FRENK NE, LI DK, et al. Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement[J]. PLoS One, 2019, 14(5): e0217442. DOI: 10.1371/journal.pone.0217442.
    [6]
    SARWAR A, ZHOU L, NOVACK V, et al. Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States[J]. Hepatology, 2018, 67(2): 690-699. DOI: 10.1002/hep.29354.
    [7]
    JIANG ZS, JIANG JN. The progress of evaluating the liver store function of the End-stage Liver Disease[J]. Med Recapitulate, 2006, 17: 1075-1077. DOI: 10.3969/j.issn.1006-2084.2006.17.025.

    蒋忠胜, 江建宁. 评价终末期肝病肝脏储备功能的进展[J]. 医学综述, 2006, 17: 1075-1077. DOI: 10.3969/j.issn.1006-2084.2006.17.025.
    [8]
    PUGH RN, MURRAY-LYON IM, DAWSON JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60(8): 646-649. DOI: 10.1002/bjs.1800600817.
    [9]
    BANARES R, CASADO M, RODRIGUEZ-LAIZ JM, et al. Urgent transjugular intrahepatic portosystemic shunt for control of acute variceal bleeding[J]. Am J Gastroenterol, 1998, 93(1): 75-79. DOI: 10.1111/j.1572-0241.1998.075_c.x.
    [10]
    JALAN R, ELTON RA, REDHEAD DN, et al. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic protosystemic stent-shunt for variceal haemorrhage[J]. J Hepatol, 1995, 23(2): 123-128. DOI: 10.1016/0168-8278(95)80325-4.
    [11]
    YUAN SS, HAN GH, FAN DM. TIPS treatment of the complications of portal hypertension: the current status of its prognostic evaluation[J]. J Intervent Radiol, 2011, 20(3): 245-248. DOI: 10.3969/j.issn.1008-794X.2011.03.018.

    原姗姗, 韩国宏, 樊代明. TIPS治疗门静脉高压并发症预后评价的现状[J]. 介入放射学杂志, 2011, 20(3): 245-248. DOI: 10.3969/j.issn.1008-794X.2011.03.018.
    [12]
    KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470. DOI: 10.1053/jhep.2001.22172.
    [13]
    KIM HJ, LEE HW. Important predictor of mortality in patients with end-stage liver disease[J]. Clin Mol Hepatol, 2013, 19(2): 105-115. DOI: 10.3350/cmh.2013.19.2.105.
    [14]
    MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 1: 864-871. DOI: 10.1053/he.2000.5852.
    [15]
    KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470. DOI: 10.1053/jhep.2001.22172.
    [16]
    ZHOU CZ, HOU CL, CHENG DL, et al. Predictive accuracy comparison of MELD and Child-Turcotte-Pugh scores for survival in patients underwent TIPS placement: a systematic meta-analytic review[J]. Int J Clin Exp Med, 2015, 8(8): 13464-13472.
    [17]
    BIGGINS SW, KIM WR, TERRAULT NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterol, 2006, 130(6): 1652-1660
    [18]
    GUY J, SOMSOUK M, SHIBOSKI S, et al. New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt[J]. Clin Gastroenterol Hepatol, 2009, 7(11): 1236-1240. DOI: 10.1016/j.cgh.2009.06.009.
    [19]
    AHMED R, SANTHANAM P, RAYYAN Y. MELD-Na as a prognostic indicator of 30-and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemic shunt[J]. Eur J Gastroenterol Hepatol, 2015, 27(10): 1226-1227. DOI: 10.1097/MEG.0000000000000412.
    [20]
    HEUMAN DM, ABOU-ASSI SG, HABIB A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death[J]. Hepatology, 2004, 40: 802-810. DOI: 10.1002/hep.20405.
    [21]
    RUF AE, KREMERS WK, CHAVEZ LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone[J]. Liver Transpl, 2005, 11: 336-343. DOI: 10.1002/lt.20329.
    [22]
    GINES P, ARROYO V, QUINTERO E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study[J]. Gastroenterology, 1987, 93: 234-241. DOI: 10.1016/0016-5085(87)91007-9.
    [23]
    JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6): 550-558. DOI: 10.1200/JCO.2014.57.9151.
    [24]
    RONALD J, WANG Q, CHOI SS, et al. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation[J]. Diagn Interv Imaging, 2018, 99(3): 163-168. DOI: 10.1016/j.diii.2017.10.008.
    [25]
    ROAYAIE S, JIBARA G, BERHANE S, et al. 851 PALBI-An objective score based on platelets, albumin bilirubin stratifies HCC patients undergoing resection & ablation better than child's classification[J]. Hepatology, 2015, 62(Suppl 1): 624A-690A. DOI: 10.1002/hep.28219.
    [26]
    OIKONOMOU T, GOULIS L, DOUMTSIS P, et al. ALBI and PALBI grades are associated with the outcome of patients with stable decompensated cirrhosis[J]. Ann Hepatol, 2019, 18(1): 126-136. DOI: 10.5604/01.3001.0012.7904.
    [27]
    ELSHAARAWY O, ALLAM N, ABDELSAMEEA E, et al. Platelet-albumin-bilirubin score-a predictor of outcome of acute variceal bleeding in patients with cirrhosis[J]. World J Hepatol, 2020, 12(3): 99-107. DOI: 10.4254/wjh.v12.i3.99.
    [28]
    KHABBAZ RC, LOKKEN RP, CHEN YF, et al. Albumin-Bilirubin and Platelet-Albumin-Bilirubin grades do not predict survival after transjugular intrahepatic portosystemic shunt creation[J]. Cardiovasc Intervent Radiol, 2018, 41(7): 1029-1034. DOI: 10.1007/s00270-018-1923-2
    [29]
    JALAN R, PAVESI M, SALIBA F, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure[J]. J Hepatol, 2015, 62(4): 831-840. DOI: 10.1016/j.jhep.2014.11.012
    [30]
    STURM L, PRAKTIKNJO M, BETTINGER D, et al. Prognostic value of the CLIF-C AD score in patients with implantation of transjugular intrahepatic portosystemic shunt[J]. Hepatol Commun, 2021, 5(4): 650-660. DOI: 10.1002/hep4.1654.
    [31]
    BETTINGER D, STURM L, PFAFF L, et al. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival[J]. J Hepatol, 2021, 74(6): 1362-1372. DOI: 10.1016/j.jhep.2021.01.023.
    [32]
    CHAPIN SE, GOLDBERG DS, KAPLAN DE, et al. External validation of the FIPS score for post-TIPS mortality in a national veterans affairs cohort[J]. Dig Dis Sci, 2021, 67(9): 4581-4589. DOI: 10.1007/s10620-021-07307-5.
    [33]
    YANG CT, CHEN QY, ZHOU C, et al. FIPS score for prediction of survival after TIPS placement: external validation and comparison with traditional risk scores in a cohort of Chinese patients with cirrhosis[J]. AJR Am J Roentgenol, 2022, 219(2): 255-267. DOI: 10.2214/AJR.21.27301.
    [34]
    LIU SY, LI LH, LI SX, et al. Predictive value of controlled nutritional status score for overt hepatic encephalopathy after transjugular intrahepatic portosystemic stent-shunt of Budd-Chiari syndrome[J]. Chin J Dig Surg, 2023, 22(2): 260-267. DOI: 10.3760/cma.j.cn115610-20221205-00733.

    刘胜炎, 李路豪, 李素新, 等. 控制营养状况评分对布-加综合征患者行经颈静脉肝内门腔内支架分流术后发生显性肝性脑病的预测价值[J]. 中华消化外科杂志, 2023, 22(2): 260-267. DOI: 10.3760/cma.j.cn115610-20221205-00733.
    [35]
    GABA RC, COUTURE PM, BUI JT, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation[J]. J Vasc Interv Radiol, 2013, 24(3): 411-420. e1-4;quiz 421. DOI: 10.1016/j.jvir.2012.10.026.
    [36]
    ZHANG YF, CHEN P. Prognosis of transjugular intrahepatic portosystemic shunt[J]. Chin J Min Inv Surg, 2018, 18(5): 457-461. DOI: 10.3969/j.issn.1009-6604.2018.05.019.

    张艳飞, 陈平. 经颈静脉肝内门体静脉分流术的预后研究进展[J]. 中国微创外科杂志, 2018, 18(5): 457-461. DOI: 10.3969/j.issn.1009-6604.2018.05.019.
    [37]
    PRAKTIKNJO M, BOOK M, LUETKENS J, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis[J]. Hepatology, 2018, 67(3): 1014-1026. DOI: 10.1002/hep.29602.
    [38]
    ZHANG BT, XU Y, YANG XF, et al. Association of sarcopenia with prognosis after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis[J]. J Clin Hepatol, 2021, 37(12): 2932-2934. DOI: 10.3969/j.issn.1001-5256.2021.12.041.

    张帮婷, 胥莹, 杨雪芳, 等. 肝硬化肌少症与经颈静脉肝内门体分流术预后的关系[J]. 临床肝胆病杂志, 2021, 37(12): 2932-2934. DOI: 10.3969/j.issn.1001-5256.2021.12.041.
    [39]
    TONEY LK, VESSELLE HJ. Neural networks for nodal staging of non-small cell lung cancer with FDG PET and CT: importance of combining uptake values and sizes of nodes and primary tumor[J]. Radiology, 2014, 270(1): 91-98. DOI: 10.1148/radiol.13122427.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (364) PDF downloads(46) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return